ICU Medical (NASDAQ:ICUI) Upgraded by StockNews.com to “Buy” Rating

StockNews.com upgraded shares of ICU Medical (NASDAQ:ICUI) from a hold rating to a buy rating in a research note released on Wednesday morning.

Several other analysts also recently weighed in on the company. Raymond James boosted their price objective on ICU Medical from $158.00 to $190.00 and gave the company an “outperform” rating in a research report on Thursday, September 12th. KeyCorp upped their price target on shares of ICU Medical from $198.00 to $209.00 and gave the company an “overweight” rating in a report on Wednesday, November 13th. Jefferies Financial Group initiated coverage on shares of ICU Medical in a research report on Monday, October 14th. They set a “hold” rating and a $183.00 price target for the company. Finally, Needham & Company LLC restated a “hold” rating on shares of ICU Medical in a research report on Wednesday, November 13th. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat, ICU Medical currently has a consensus rating of “Moderate Buy” and a consensus price target of $173.00.

ICU Medical Trading Down 1.2 %

ICUI opened at $167.59 on Wednesday. ICU Medical has a 12 month low of $82.82 and a 12 month high of $196.26. The company has a current ratio of 2.29, a quick ratio of 1.03 and a debt-to-equity ratio of 0.75. The business’s 50-day moving average price is $176.54 and its 200-day moving average price is $144.46.

Insider Buying and Selling

In other ICU Medical news, VP Daniel Woolson sold 2,502 shares of the firm’s stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $163.22, for a total value of $408,376.44. Following the completion of the sale, the vice president now directly owns 13,107 shares in the company, valued at $2,139,324.54. This trade represents a 16.03 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CEO Vivek Jain sold 12,000 shares of ICU Medical stock in a transaction that occurred on Tuesday, October 1st. The shares were sold at an average price of $178.46, for a total value of $2,141,520.00. Following the sale, the chief executive officer now directly owns 104,593 shares in the company, valued at approximately $18,665,666.78. The trade was a 10.29 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 38,502 shares of company stock valued at $6,573,496 over the last quarter. 6.70% of the stock is owned by company insiders.

Institutional Investors Weigh In On ICU Medical

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its position in ICU Medical by 0.5% during the first quarter. Vanguard Group Inc. now owns 2,452,720 shares of the medical instruments supplier’s stock valued at $263,226,000 after buying an additional 11,991 shares during the period. State Street Corp lifted its position in ICU Medical by 9.3% during the 3rd quarter. State Street Corp now owns 907,607 shares of the medical instruments supplier’s stock valued at $165,384,000 after acquiring an additional 77,506 shares during the period. Geode Capital Management LLC boosted its stake in ICU Medical by 9.6% during the third quarter. Geode Capital Management LLC now owns 546,954 shares of the medical instruments supplier’s stock worth $99,687,000 after acquiring an additional 48,106 shares in the last quarter. Dimensional Fund Advisors LP grew its holdings in ICU Medical by 21.7% in the second quarter. Dimensional Fund Advisors LP now owns 311,542 shares of the medical instruments supplier’s stock worth $36,996,000 after purchasing an additional 55,588 shares during the period. Finally, Charles Schwab Investment Management Inc. increased its stake in shares of ICU Medical by 10.2% during the third quarter. Charles Schwab Investment Management Inc. now owns 301,107 shares of the medical instruments supplier’s stock valued at $54,868,000 after purchasing an additional 27,927 shares in the last quarter. 96.10% of the stock is owned by hedge funds and other institutional investors.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.